Portola Pharmaceuticals, Inc.
270 E Grand Avenue
Suite 2240
Phone: (650) 244-6864p:650 244-6864 South San Francisco, CA  94080-4811  United States Fax: (302) 636-5454f:302 636-5454

This company was Merged or Acquired on 7/2/2020.
This company ceased filing statements with the SEC on 7/13/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

PORTOLA PHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers

New York, 1/26/2015 (CRMZ News Service) -- The following information has been extracted from the SEC Filing:

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 26, 2015, Robert Califf, M.D., submitted his resignation as an independent director of the Board of Directors of Portola Pharmaceuticals, Inc. (the "Company"), effective immediately. Dr. Califf was serving as a member of the Nominating and Corporate Governance Committee of the Board of Directors prior to his resignation. Dr. Califf resigned to accept a position as the Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration. Dr. Califf's resignation was not the result of any disagreement with Portola on any matter relating to its operations, policies, or practices. Effective as of his resignation, Dr. Califf is no longer a member of the Board of Directors or any of its committees.

Portola thanks Dr. Califf for his contributions to the Board of Directors.


View the complete 8-K filing.


Related Businesses
- - Customer

Copyright © 2022 by (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by, Inc. Except as expressly permitted by, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable., Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Thursday, January 20, 2022